레벨레이션 바이오사이언시스 (REVB) 주가 전망: 목표주가, 배당, 최신 뉴스

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response.

It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc.

was incorporated in 2019 and is based in San Diego, California.

Revelation Biosciences, Inc.는 임상 단계의 생명과학 기업으로, 염증 반응을 재조정해 건강을 최적화하는 데 주력하고 있습니다.

주요 후보물질인 Gemini는 phosphorylated hexaacyl disaccharide (PHAD)의 독점 제형 플랫폼으로, Toll-like receptor 4 (TLR) 작용제로서 교란된 염증 반응을 조절·재균형화합니다. 회사는 선천성 면역계를 조절하는 치료제를 개발·상용화하여 질병을 예방하고 치료하는 데 주력하고 있으며, 여기에는 급성 신손상 예방·치료용 잠재 치료제 GEM-AKI와 만성 신장질환 예방·치료용 GEM-CKD가 포함됩니다.

회사는 2019년에 설립되었고 본사는 캘리포니아주 샌디에이고에 위치해 있습니다. 이전 명칭은 Petra Acquisition, Inc.였으며 2022년 1월에 현재 명칭인 Revelation Biosciences, Inc.로 변경했습니다.

• 주소: 4660 La Jolla Village Drive, Suite 100, San Diego, CA 92122, United States

• 전화번호: 650 800 3717

• 웹사이트: https://www.revbiosciences.com

• 섹터: Healthcare

• 산업: Biotechnology

• 직원 수: 8